-
- Posts: 4
- Joined: Tue Sep 19, 2023 6:35 pm
- Location: United States
When I dilute the placebo in a spiking solution that is 0.01 mg EHG / mL IPA, the EHG peak response is greater than when I inject the spiking solution by itself. Hopefully that makes sense. I would expect the EHG concentration to be the same regardless of the presence of placebo.
When the placebo is diluted in pure IPA, there are no peaks interfering with the EHG RT. There are peaks eluting just before and just after where EHG would elute. These peaks remain present in the spiked placebo, so I don't think that this is interference adding to the EHG area count.
I'm using a 35% phenyl (ZB-35HT) 30m x 0.25 um x 0.320mm column.
Initially I thought that derivatizing the solutions with BSTFA w/ 1% TMS would solve my problems but I'm having some issues getting the reaction to go to completion, or find a similar substance to use as an internal standard.
Another thing I tried was using a standard addition technique to quantitate the recovery. This actually worked the first time that I tried it, but then the next time that I tried this, the recoveries were significantly different. I don't feel like this is a very robust method.
I came across some research papers discussing ways to overcome "matrix effect" and one of the papers presented the idea of using "protecting groups" to outcompete the sample matrix for active sites in the GC. They looked at the effect of adding a concentrated spike of very polar molecules to solutions containing pesticide sample matrix. What they found was that the addition of polar molecules caused an increase in response for a lot of their polar analytes. It was hypothesized that the mechanism behind the phenomenon is basically the GC is going to prevent a certain number of polar molecules every injection from reaching the detector. By purposely saturating the solution in polar protecting groups, the less polar analytes of interest are protected from the GC and make it to the detector.
One of the "protecting groups" was Glycerin. I am assuming that what is happening is basically what they described in their research. My EHG is being protected by the Glycerin in my placebo, so the amount of EHG that makes it to the detector is higher than in the spiking solution which contains no placebo and therefore no protecting group.
LLE to remove matrix components has proved challenging as the product is an emulsion.
Any thoughts or similar experiences? I'm hoping someone else went through something similar and has an idea of which thread I should be following.